AULOS BIOSCIENCE’S IMNESKIBART DEMONSTRATES OUTSTANDING PHASE 2 ACTIVITY IN CHECKPOINT INHIBITOR-REFRACTORY MELANOMA AND LUNG CANCER, COMPARING FAVORABLY WITH HISTORICAL TREATMENT BENCHMARKS

Reuters · 1d ago

Please log in to view news